NAMS - NewAmsterdam Pharma Company N.V. Ordinary Shares

NAMS - NewAmsterdam Pharma Company N.V. Ordinary Shares

https://www.newamsterdampharma.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

NewAmsterdam ( NAMS ) Q2 Revenue Jumps 49%

Motley Fool • 1 month, 1 week ago • score: 0.11

NewAmsterdam Pharma ( NASDAQ:NAMS ) , a clinical-stage biopharmaceutical company focused on developing oral therapies for cardiometabolic diseases, delivered its Q2 2025 earnings report on August 6, 2025. The most important news from the release was GAAP revenue of $19.1 million, a significant ...

NewAmsterdam Pharma Company N.V. ( NAMS ) Reports Q2 Loss, Tops Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.04

NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of +71.15% and +486.19%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

GlobeNewswire • 3 months, 2 weeks ago • score: 0.06

NAARDEN, the Netherlands and MIAMI, May 27, 2025 ( GLOBE NEWSWIRE ) -- NewAmsterdam Pharma Company N.V. ( Nasdaq: NAMS or "NewAmsterdam" or the "Company" ) , a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ( ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$27.29

52W Low

$14.06

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.01

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

27.63

EV/Revenue (<3 favorable)

35.97

P/S (TTM) (<3 favorable)

47.51

P/B (<3 favorable)

3.91

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.39%

Institutions (25–75% balanced)

107.05%

Shares Outstanding

112,628,000

Float

54,895,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

64,006,000

Gross Profit (TTM)

64,006,000

EPS (TTM)

-1.59

Profit Margin (>10% good)

-2.59%

Operating Margin (TTM) (higher better)

-1.86%

ROE (TTM) (>15% strong)

-0.28%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

7.40

Momentum

Bearish momentum

Value

0.7423

Previous

0.9948

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025